Key facts
- China concluded drug price negotiations for its 2026 national reimbursement list on Wednesday.
- The talks covered 664 drug applications.
- 557 applications were approved for the basic national health-insurance list.
- 58 applications were approved for the commercial-insurance innovative-drug list.
China concluded negotiations over drug prices for its 2026 national reimbursement lists on Wednesday, more than a month earlier than in prior years. Beijing is seeking to expand access to innovative medicines while containing pressure on its basic health-insurance fund. The nearly five-day negotiations in Beijing covered 664 drug applications. Of those, 557 applications for the basic national health-insurance list passed the initial review, 23 more than last year. Another 58 applications for the commercial-insurance innovative-drug list passed, down 63 from a year earlier.
Discussion